MarketPR

Medtronic fiscal 2026 revenue hits decade-high as cardiovascular strength and restructuring shift the setup

9/4/2026

A fiscal 2026 revenue print of $36.4 billion puts Medtronic (NYSE: MDT) in focus.

The 8.4% gain, with 5.8% organic growth, was the company's strongest top-line result in ten years, and the cardiovascular segment drove it, posting 9.3% organic expansion while accounting for more than 38% of enterprise revenue.

Guidance for fiscal 2027 targets 7.25% to 7.75% organic growth, above the company's historical average of roughly 5%.

Behind the print: restructuring and capacity Over the past year, Medtronic pruned its workforce, overhauled its cardiovascular operations, announced the closure of its Santa Rosa campus, and spun off its diabetes business as a separately listed company, MiniMed (NASDAQ: MMED).